ALX ONCOLOGY HOLDINGS INC

Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.

ALXO | US

Overview

Corporate Details

ISIN(s):: US00166B1052
LEI:
Country:: United States of America
Address:: 323 ALLERTON AVENUE, 94080 SOUTH SAN FRANCISCO
Website:: https://alxoncology.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies that harness the immune system to combat cancer. The company's lead therapeutic candidate, evorpacept, is a next-generation CD47 checkpoint inhibitor designed to block a key signal that cancer cells use to evade immune detection. ALX Oncology is advancing evorpacept in multiple clinical trials as a potential cornerstone therapy for use in combination with other anti-cancer agents. The company's development pipeline targets a broad range of hematologic malignancies and solid tumors, with the goal of improving upon current and future standards of care for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALX ONCOLOGY HOLDINGS INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALX ONCOLOGY HOLDINGS INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALX ONCOLOGY HOLDINGS INC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

	Company	Country	Ticker
	Legend Biotech Corp Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.	United States of America	LEGN
	LENZ Therapeutics, Inc. Develops a prescription eye drop for presbyopia, the age-related loss of near vision.	United States of America	LENZ
	Lexaria Bioscience Corp. Biotech firm with patented technology improving oral drug delivery and absorption.	United States of America	LEXX
	Lexeo Therapeutics, Inc. Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.	United States of America	LXEO
	LEXICON PHARMACEUTICALS, INC. Develops gene-based drugs for chronic diseases, including treatments for heart failure.	United States of America	LXRX
$LIFECORE BIOMEDICAL, INC. \DE\ Logo$	LIFECORE BIOMEDICAL, INC. \DE\ A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).	United States of America	LFCR
	Liminatus Pharma, Inc. Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.	United States of America	LIMN
	Lineage Cell Therapeutics Inc. Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.	Israel	LCTX
	Lipigon Pharmaceuticals AB Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.	Sweden	LPGO
	Lipocine Inc. Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.	United States of America	LPCN